Categories: Technology

TRANSOCEAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Transocean Ltd. – RIG

NEW ORLEANS, Jan. 22, 2025 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 24, 2025 to file lead plaintiff applications in a securities class action lawsuit against Transocean Ltd. (the “Company”) (NYSE: RIG), if they purchased the Company’s securities between October 31, 2023 and September 2, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Get Help

Transocean investors should visit us at https://claimsfiler.com/cases/nyse-rig-2/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Transocean and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (1) the Discoverer Inspiration and the Development Driller III were considered non-strategic assets; (2) the Company’s recorded asset valuations were overstated; (3) as a result, the Company would take nearly twice the vessels’ sale price in impairment if sold; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On September 3, 2024, pre-market, the Company disclosed that it had agreed to sell the Development Driller III and the Discoverer Inspiration rigs and associated assets for an aggregate $342 million “as part of the Company’s effort to dispose of non-strategic assets,” which would result in an estimated third-quarter non-cash charge of up to $645 million associated with the impairment of said assets. On this news, the price of Transocean’s shares fell $0.42, or 8.86%, to close at $4.32 per share on September 3, 2024, on unusually heavy trading volume.

The case is Gábor v. Transocean Ltd., et al., No. 24-cv-9964.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

GlobeNews Wire

Recent Posts

STG Energy Expands Bitcoin Cloud Mining Services Amid Rising Crypto Demand

LONDON, April 06, 2025 (GLOBE NEWSWIRE) -- STG Energy, a leader in Bitcoin cloud mining…

3 hours ago

Wellamoon Reviews [Read Before Buying]: Do Wellamoon Sleep Patches Really Work?

FRANKLIN SQUARE, N.Y., April 06, 2025 (GLOBE NEWSWIRE) -- You are not the only person…

3 hours ago

#XRP looks very optimistic – big things are happening! Earn amazing high yield profits every day with cloud mining!

London, UK, April 05, 2025 (GLOBE NEWSWIRE) -- The cryptocurrency universe is filled with anticipation…

3 hours ago

NiteHush Pro: Introducing NiteHush Pro as the 7-Second Chew Hack for Snoring and Sleep Apnea Relief

TALLMADGE, Ohio, April 05, 2025 (GLOBE NEWSWIRE) -- NiteHush Pro is rapidly emerging as the…

3 hours ago

Best Free Cloud Mining Guide 2025: Earn Free Bitcoins with Cryptocurrency Mining Using HEXminer AI

London, UK, April 05, 2025 (GLOBE NEWSWIRE) -- In 2025, HEXminer has revolutionized the cloud mining industry…

3 hours ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers Disease

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate…

6 hours ago